March 28th 2024
In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Behind the FDA Approval: Pacritnib for Myelofibrosis and Severe Thrombocytopenia
March 2nd 2022In an interview with Targeted Oncology, John Mascarenhas, MD, discussed the introduction of pacritinib to the treatment landscape for myelofibrosis and severe thrombocytopenia, and the research supporting the recent FDA approval.
Read More
Future of Myelofibrosis Treatment is Moving Beyond Just JAK Inhibition
February 27th 2022The future of myelofibrosis may include several JAK inhibitor treatment niches as well as combination regimens with JAK inhibition in both the upfront and second-line setting and more, according to John Mascarenhas, MD.
Read More
Interferon Use in Patients with Myeloproliferative Neoplasms
January 11th 2022Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.
Watch
The Expanding Role of Interferons in Myeloproliferative Neoplasms
November 24th 2021In an interview with Targeted Oncology™, Richard T. Silver, MD, discussed the role of interferon in the treatment of myeloproliferative neoplasm as well as the importance of the 3-year global MPN initiative being conducted by the MPN Research Foundation.
Read More
Treating Post-MPN Acute Leukemia Remains an Unmet Medical Need
October 18th 2021In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.
Read More
Unmet Needs Loom for Later-Line Options in MPNs
October 13th 2021Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses the need for new drugs after patients with myelofibrosis are treated with JAK inhibitors.
Watch